Understanding The Requirements For Effective Nasal Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Understanding The Requirements For Effective Nasal Drug Delivery


Pharmaceutical Technology Europe
Volume 22, Issue 9

Conclusion

To achieve optimal product performance, nasal spray developers need to manipulate device and formulation parameters on the basis of detailed understanding. Laser diffraction is a valuable technique for accessing relevant information because it captures droplet size data in real time, enabling researchers to evaluate the impact of any change. The influence of formulation properties such as viscosity and device parameters, including actuation profile, spray pump mechanism and actuator orifice size, can be systematically studied to facilitate a knowledge-based approach, as the presented data show. The recommendation by the regulators of laser diffraction as a measurement technique, relevant across the complete product lifecycle, from development through to quality control, underlines its value.

Paul Kippax is Product Manager — Diffraction Products at Malvern Instruments Ltd., UK. Tel. +44 (0)1684 892 456
.

Julie Suman is President at NextBreath LLC, USA.

Gerallt Williams is Director, R&D Laboratory Services at AptarGroup SAS, France.

References

1. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products — Chemistry, Manufacturing, and Controls Documentation (FDA, USA, July 2002). http://www.fda.gov/

2. Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action (FDA, USA, April 2003). http://www.fda.gov/

3. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products (European Medicines Agency, London, UK, June 2006). http://www.ema.europa.eu

4. Data on file at Malvern Instruments.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here